Giacomo Andreani,Daniela Cilloni
Giacomo Andreani
Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measurable residual disease (MRD) after induction and consolidation chemo...
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens [0.03%]
CD5在双打击弥漫大B细胞淋巴瘤中的预后价值及其DA-EPOCH-R/R-CHOP疗效比较研究
Fangwen Zhang,Ling Li,Lei Zhang et al.
Fangwen Zhang et al.
Objectives: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH-R) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine and ...
IDH1-mutated relapsed or refractory AML: current challenges and future prospects [0.03%]
IDH1突变的复发或难治性AML：当前挑战与未来前景
Juan Eduardo Megías-Vericat,Octavio Ballesta-López,Eva Barragán et al.
Juan Eduardo Megías-Vericat et al.
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1 mut ), present in 7-14% of AML patients, have been discov...
Andres Lopez,Pau Abrisqueta
Andres Lopez
Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large neoplastic cells, most of them resembling plasmablasts that have a CD20-negative phenotype. Although initially described as being associated with HIV, over t...
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia [0.03%]
近年来B细胞急性淋巴细胞白血病的生物和治疗学进展
Mehrdad Hefazi,Mark R Litzow
Mehrdad Hefazi
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult...
Current understanding of the role and regulation of miRNAs in Burkitt lymphoma [0.03%]
关于miRNA在Burkitt淋巴瘤中作用和调控的当前认识
Alessandro Davide Videtta,Valeria Malagnino,Giulia De Falco
Alessandro Davide Videtta
Since its discovery in 1958, Burkitt lymphoma (BL) has been extensively studied and has become a model for tumorigenesis, but its pathogenesis has not been completely explained and understood yet. The aim of this review was to summarize the...
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions [0.03%]
冒烟型多发性骨髓瘤的流行率及目前关于治疗决策的研究证据指导原则
Agnieszka Blum,Despina Bazou,Peter O&#x;Gorman
Agnieszka Blum
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined signific...
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era [0.03%]
正电子发射断层扫描时代化疗后晚期霍奇金淋巴瘤的结局和复发模式
Carminia Lapuz,Anoop K Enjeti,Peter C O&#x;Brien et al.
Carminia Lapuz et al.
Background: This study evaluated relapse patterns and survival in advanced Hodgkin lymphoma (HL) patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) with positron emission tomography (PET) use...
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [0.03%]
用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的 Ponatinib 的用药指征及前景展望
Theodora Anagnostou,Mark R Litzow
Theodora Anagnostou
Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are eit...